Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: Implications for ascites formation

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5224-5229

  Belotti, Dorina ^a   Paganoni, Paola ^a   Manenti, Luigi ^a   Garofalo, Angela ^a   Marchini, Sergio ^a   Taraboletti, Giulia ^a   Giavazzi, Raffaella ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; GELATINASE A; GELATINASE B; SEMAXANIB; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN SECRETION; TUMOR XENOGRAFT; VASCULAR ENDOTHELIUM;

ANIMALS; ASCITES; CELL MOVEMENT; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL GROWTH FACTORS; ENZYME ACTIVATION; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PERITONEAL CAVITY; PHENYLALANINE; THIOPHENES; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0141482154     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kohn, E. C. Angiogenesis in ovarian carcinoma: a formidable biomarker. Cancer (Phila.), 80: 2219-2221, 1997.
2. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
3. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13: 9-22, 1999.
4. Park, J. E., Keller, G. A., and Ferrara, N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell, 4: 1317-1326, 1993.
5. Boocock, C. A., Charnock-Jones, D. S., Sharkey, A. M., McLaren, J., Barker, P. J., Wright, K. A., Twentyman, P. R., and Smith, S. K. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J. Natl. Cancer Inst. (Bethesda), 87: 506-516, 1995.
6. Manenti, L., Paganoni, P., Floriani, I., Torri, W., Buda, A., Taraboletti, G., Landoni, F., Labianca, R., Belotti, D., and Giavazzi, R. Expression level of vascular endothelial growth factor, matrix metalloproteinase 2 & 9 and tissue inhibitor of metalloproteinases 1 & 2 in plasma of patients with ovarian carcinoma. Eur. J. Cancer, 39: 1948-1956, 2003.
7. Xu, L., Yoneda, J., Herrera, C., Wood, J., Killion, J. J., and Fidler, I. J. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. Oncol., 16: 445-454, 2000.
8. Xu, J., Rodriguez, D., Petitclerc, E., Kim, J. J., Hangai, M., Moon, Y. S., Davis, G. E., Brooks, P. C., and Yuen, S. M. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol., 154: 1069-1079, 2001.
9. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol., 2: 737-744, 2000.
10. Pozzi, A., Moberg, P. E., Miles, L. A., Wagner, S., Soloway, P., and Gardner, H. A. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. USA, 97: 2202-2207, 2000.
11. Huang, S., Van Arsdall, M., Tedjarati, S., McCarty, M., Wu, W., Langley, R., and Fidler, I. J. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst. (Bethesda), 94: 1134-1142, 2002.
12. Naylor, M. S., Stamp, G. W., Davies, B. D., and Balkwill, F. R. Expression and activity of MMPS and their regulators in ovarian cancer. Int. J. Cancer, 58: 50-56, 1994.
13. Stack, M. S., Ellerbroek, S. M., and Fishman, D. A. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int. J. Oncol., 12: 569-576, 1998.
14. Giavazzi, R., Garofalo, A., Ferri, C., Lucchini, V., Bonc, E. A., Chiari, S., Brown, P. D., Nicoletti, M. I., and Taraboletti, G. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res., 4: 985-992, 1998.
15. Massazza, G., Tomasoni, A., Lucchini, V., Allavena, P., Erba, E., Colombo, N., Mantovani, A., D'Incalci, M., Mangioni, C., and Giavazzi, R. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int. J. Cancer, 44: 494-500, 1989.
16. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., and Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res., 2: 1843-1849, 1996.
17. Knox, A., Corbett, L., Stocks, J., Holland, E., Zhu, Y., and Pang, L. Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism. FASEB J., 15: 2480-2488, 2001.
18. Marchini, S., Codegoni, A., Bonazzi, C., Chiari, S., and Broggini, M. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumors. Br. J. Cancer, 76: 146-149, 1997.
19. Belotti, D., Rieppi, M., Nicoletti, M. I., Casazza, A. M., Fojo, T., Taraboletti, G., and Giavazzi, R. Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin. Cancer Res., 2: 1725-1730, 1996.
20. Taraboletti, G., Garofalo, A., Belotti, D., Drudis, T., Borsotti, P., Scanziani, E., Brown, P. D., and Giavazzi, R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst. (Bethesda), 87: 293-298, 1995.
21. Coussens, L. M., Tinkle, C. L., Hanahan, D., and Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103: 481-490, 2000.
22. Mendel, D. B., Laird, A. D., Smolich, B. D., Blake, R. A., Liang, C., Hannah, A. L., Shaheen, R. M., Ellis, L. M., Weitman, S., Shawver, L. K., and Cherrington, J. M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des., 15: 29-41, 2000.
23. Vlodavsky, I., Folkman, J., Sullivan, R., Fridman, R., Ishai-Michaeli, R., Sasse, J., and Klagsbrun, M. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc. Natl. Acad. Sci. USA, 84: 2292-2296, 1987.
24. Levi, E., Fridman, R., Miao, H. Q., Ma, Y. S., Yayon, A., and Vlodavsky, I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl. Acad. Sci. USA, 93: 7069-7074, 1996.
25. Gearing, A. J., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature, 370: 555-557, 1994.
26. Suzuki, M., Raab, G., Moses, M. A., Fernandez, C. A., and Klagsbrun, M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem., 272: 31730-31737, 1997.